These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15937458)

  • 1. Idle computers get busy screening drug targets for cancer.
    Erickson AK
    Nat Med; 2005 Jun; 11(6):584. PubMed ID: 15937458
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of molecular cancer therapeutics.
    van Montfort RL; Workman P
    Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darpones and water-soluble aminobutoxylated darpone derivatives are distinguished by matrix COMPARE analysis.
    Prühs C; Kunick C
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1850-4. PubMed ID: 17296296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
    Park H; Jung SK; Jeong DG; Ryu SE; Kim SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2250-5. PubMed ID: 18358718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a drug-like G-quadruplex binding ligand by high-throughput docking.
    Ma DL; Lai TS; Chan FY; Chung WH; Abagyan R; Leung YC; Wong KY
    ChemMedChem; 2008 Jun; 3(6):881-4. PubMed ID: 18383062
    [No Abstract]   [Full Text] [Related]  

  • 7. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein.
    Chen J; Nikolovska-Coleska Z; Wang G; Qiu S; Wang S
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5805-8. PubMed ID: 16962773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues.
    Congiu C; Cocco MT; Onnis V
    Bioorg Med Chem Lett; 2008 Feb; 18(3):989-93. PubMed ID: 18164978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines.
    Kojima N; Hayashi H; Suzuki S; Tominaga H; Maezaki N; Tanaka T; Yamori T
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6451-3. PubMed ID: 18993063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 1-(3',4',5'-trimethoxy) phenyl naphtho[2,1b]furan as a novel anticancer agent.
    Srivastava V; Negi AS; Kumar JK; Faridi U; Sisodia BS; Darokar MP; Luqman S; Khanuja SP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):911-4. PubMed ID: 16297622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and development of water-soluble curcumin conjugates as potential anticancer agents.
    Safavy A; Raisch KP; Mantena S; Sanford LL; Sham SW; Krishna NR; Bonner JA
    J Med Chem; 2007 Nov; 50(24):6284-8. PubMed ID: 17973470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
    Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies of targeting ligands against breast cancer cells.
    Yao N; Xiao W; Meza L; Tseng H; Chuck M; Lam KS
    J Med Chem; 2009 Nov; 52(21):6744-51. PubMed ID: 19835381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
    Awale M; Mohan CG
    J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship studies of cytotoxic anhydrovinblastine amide derivatives.
    Shao Y; Zhang HK; Ding H; Quan HT; Lou LG; Hu LH
    J Nat Prod; 2009 Jun; 72(6):1170-7. PubMed ID: 19499938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WinDock: structure-based drug discovery on Windows-based PCs.
    Hu Z; Southerland W
    J Comput Chem; 2007 Nov; 28(14):2347-51. PubMed ID: 17476686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-protein interactions as targets for small-molecule therapeutics in cancer.
    White AW; Westwell AD; Brahemi G
    Expert Rev Mol Med; 2008 Mar; 10():e8. PubMed ID: 18353193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.